Sickle Blow For Pfizer’s Rivipansel At Phase III RESETs Expectations
After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint. Shares in rivipansel’s originator GlycoMimetics halved on the news.
You may also be interested in...
Three new drugs for sickle cell disease could be on the market in the US next year, representing a groundswell of advancement for the devastating blood disorder that has had limited options.
The company's NDA for voxelotor was accepted by the US FDA for priority review with action expected in February, setting up a showdown with Novartis.
The latest drug development news and highlights for our US FDA Performance Tracker.